MYD88 and rheumatoid arthritis: Beyond the MyD88 dimerization inhibition, ST2825 significantly decreased the expression of MYD88. This effect might be attributed to the decreased level of its transcriptional activator E2F2, suggesting an additional regulatory mechanism for inflammation in RA orchestrated by ST2825 [27].